Compare Danaher Corporation (DHR) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs JPMorgan Chase & Co — how do they compare? Danaher Corporation trades at $200.3 (market cap $140.88B), while JPMorgan Chase & Co trades at $347.81 (market cap $911.47B). The key difference: JPMorgan Chase & Co is far larger — about 6.5× Danaher Corporation's market cap, and JPMorgan Chase & Co pays the higher dividend (1.75%). Which is the better fit depends on your goals.
| DHR | JPM | |
|---|---|---|
Market Cap | $140.88B | $911.47B |
Sector | Health | Financials |
52-Week High | $242.05 | $342.89 |
52-Week Low | $161.91 | $282.84 |
Enterprise Value | $153.66B | — |
Dividend Yield | 0.8% | 1.75% |
Volume | — | 10,479,943 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
JPMorgan Chase (JPM) trades at $347.74, up 3.95% on the day, with a bullish technical outlook and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, with Q3 results pending. The stock shows robust fundamentals including a 31.61% net income margin and 17.03% ROE, though cash flow trends indicate significant financing activity. Market sentiment is positive amid upcoming bank earnings and macroeconomic commentary from CEO Jamie Dimon.
The outlook for JPM remains favorable with a consensus price target of $377.75, suggesting upside potential. Key opportunities include earnings momentum and sector leadership, while risks involve geopolitical tensions, cybersecurity threats, and volatile cash flows. Institutional holdings reflect confidence, but investors should monitor interest rate impacts and economic guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
